company background image
ATE

Antibe Therapeutics TSX:ATE Stock Report

Last Price

CA$0.60

Market Cap

CA$31.3m

7D

-7.7%

1Y

-50.8%

Updated

24 Sep, 2022

Data

Company Financials +
ATE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ATE Stock Overview

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally.

Antibe Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Antibe Therapeutics
Historical stock prices
Current Share PriceCA$0.60
52 Week HighCA$1.25
52 Week LowCA$0.56
Beta-0.064
1 Month Change-4.76%
3 Month Change-7.69%
1 Year Change-50.82%
3 Year Change-84.21%
5 Year Change-33.33%
Change since IPO-89.09%

Recent News & Updates

Shareholder Returns

ATECA PharmaceuticalsCA Market
7D-7.7%-10.5%-4.8%
1Y-50.8%-66.7%-7.2%

Return vs Industry: ATE exceeded the Canadian Pharmaceuticals industry which returned -66.8% over the past year.

Return vs Market: ATE underperformed the Canadian Market which returned -7.2% over the past year.

Price Volatility

Is ATE's price volatile compared to industry and market?
ATE volatility
ATE Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement11.9%
Market Average Movement9.9%
10% most volatile stocks in CA Market18.3%
10% least volatile stocks in CA Market3.8%

Stable Share Price: ATE is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ATE's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200937Dan Legaulthttps://www.antibethera.com

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company’s drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study.

Antibe Therapeutics Inc. Fundamentals Summary

How do Antibe Therapeutics's earnings and revenue compare to its market cap?
ATE fundamental statistics
Market CapCA$31.28m
Earnings (TTM)-CA$24.48m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATE income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$24.48m
Earnings-CA$24.48m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did ATE perform over the long term?

See historical performance and comparison